Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jon Moore

Surgery Pensacola, FL Medical Doctor

NPI 1568429462 CMS profile 298148

2130 E Johnson Ave Ste 130, Pensacola, FL 32514

Open in the dashboard

General payments

$27,566

151 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jon Moore of Pensacola, FL is reported in the CMS Open Payments database as having received $27,566 across 151 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,625 29
2024 General $1,547 19
2023 General $793 19
2022 General $2,487 26
2021 General $385 11
2020 General $4,349 12
2019 General $15,381 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jon Moore
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Jon Moore were reported at $2,625. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Jon Moore Surgery median Middle half National median
2019 $15,381 $253 $82–$1,521 $163
2020 $4,349 $131 $40–$706 $114
2021 $385 $168 $50–$904 $132
2022 $2,487 $224 $76–$1,218 $149
2023 $793 $253 $82–$1,255 $160
2024 $1,547 $279 $90–$1,381 $164
2025 $2,625 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $23,592 66 payments
  2. Medical Device Business Services, Inc. $1,288 8 payments
  3. Davol Inc. $973 13 payments
  4. TELA Bio, Inc. $383 19 payments
  5. Ethicon US, LLC $270 5 payments
  6. Merck Sharp & Dohme Corporation $143 3 payments
  7. Baxter Healthcare $120 4 payments
  8. MIMEDX Group, Inc. $110 2 payments
  9. CONMED Corporation $65 2 payments
  10. Regeneron Healthcare Solutions, Inc. $54 2 payments
  11. Other $568 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $17,750 6 payments
  2. Food and Beverage $6,251 128 payments
  3. Travel and Lodging $2,565 15 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,000 2 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $21,842 64 payments
  2. DAVINCI XI $1,750 2 payments
  3. STRATAFIX $1,404 9 payments
  4. HARMONIC Product Family $1,404 9 payments
  5. ECHELON FLEX Stapler $1,288 8 payments
  6. Phasix Mesh BD Interventional Surgery $429 4 payments
  7. Phasix Mesh Surgery $374 6 payments
  8. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $353 17 payments
  9. ENTEREG $143 3 payments
  10. PHASIX $141 1 payment
  11. Other $1,408 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

144

Median for General Surgery: 59

Drug cost

$1,003

Median for General Surgery: $393

Branded share of claims

70.8%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 74 $570
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 28 $272
Neomycin Sulfate Generic 20 $111
Metronidazole Generic 22 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$188,427

Medicare's payments for the services billed

Medicare patients

340

Average age 74

Services billed

767

174 women, 166 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Ischemic heart disease 35%
Diabetes 34%
Chronic kidney disease 34%
Atrial fibrillation 28%
Cancer 28%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

151 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record